vimarsana.com
Home
Live Updates
Candesant Biomedical Announces $35M in Series B Financing to
Candesant Biomedical Announces $35M in Series B Financing to
Candesant Biomedical Announces $35M in Series B Financing to Advance Commercialization of Brella™, the First and Only FDA-cleared 3-Minute SweatControl Patch™
/PRNewswire/ -- Candesant Biomedical, Inc. ("Candesant"), a private medical device company focused on the development and commercialization of non-invasive...
Related Keywords
United States ,
Americans ,
Suzanne Haber ,
Candesant Biomedical Inc ,
Prnewswire Candesant Biomedical Inc ,
Brella Early Experience Program ,
Consumer Survey On Cosmetic Dermatologic Procedures ,
American Society For Dermatologic Surgery ,
Sweat Solutions ,
International Hyperhidrosis Society ,
Drug Administration ,
Astia Fund ,
Minute Sweatcontrol ,
Polaris Partners ,
Niquette Hunt ,
Karen Long ,
Senior Managing Director ,
Candesant Biomedical ,
American Society ,
Dermatologic Surgery ,
Brella Sweatcontrol Patch ,
Control Patch ,
Arch Dermatol Res ,
International Hyperhidrosis ,
Under Age ,
Cosmetic Dermatologic ,
Press Release ,
Accessed Feb ,
Nc ,